described variant, CYP1A1*2, is located in the 3Ј non-coding region of the CYP1A1 gene and introduces an MspI restriction The cytochrome P4501A1 (CYP1A1) enzyme is regulated endonuclease site (9, 10) . The second variant, CYP1A1*3, is at the transcriptional level and its expression is influenced strictly linked to CYP1A1*2 (7) and consists of an A→G by genetic factors, polymorphisms in the structural and transition in exon 7 that results in an amino acid substitution regulatory genes, and by environmental factors such as of Val 462 to Ile 462 (11) . Several studies have suggested that exposure to polycyclic aromatic hydrocarbons (PAHs). To this genotype increases susceptibility to various cancers, but investigate the role of CYP1A1 in breast cancer, we studied the biochemical basis is unclear. It has been assumed that the CYP1A1 expression in breast tissue, thereby taking all CYP1A1*2 and CYP1A1*3 alleles lead to higher inducibility. possible modifying factors into account. We measured Expression of CYP1A1 is regulated by the aryl hydrocarbon CYP1A1 expression in 58 non-tumor breast tissue specimens receptor, together with several other regulatory proteins. from both breast cancer patients (n ⍧ 26) and cancer-free Increased transcription of the CYP1A1 gene reflects induction individuals (n ⍧ 32) using a newly developed reverse of the enzyme (12). CYP1A1 expression can be induced by transcription-polymerase chain reaction assay. CYP1A1 expression varied between specimens~400-fold and was exposure to PAHs and organochlorines (13). Besides environindependent of age. CYP1A1 expression was somewhat mental factors, genetic factors can modify CYP1A1 expression; higher in tissue from breast cancer patients than in that these include the genotype of the structural gene and the from cancer-free individuals, but this difference was not genotype of regulatory genes, including the aryl hydrocarbon statistically significant. Analysis for CYP1A1 genetic polyreceptor. Therefore determining the amount of transcript or morphisms revealed eight variants, seven in the cancerthe actual level of the enzyme captures the influence of all free group and one in the patient group. The variant potentially modifying factors and is a more sensitive tool than genotype was not a good predictor of expression level. We the analysis of the genotype of a single gene. conclude that high CYP1A1 expression could be a risk
We have examined CYP1A1 expression as a possible breast factor for breast cancer and that the known CYP1A1 cancer risk factor by comparing CYP1A1 expression in nonpolymorphisms are not good predictors of CYP1A1 tumor breast tissue from 27 breast cancer cases and 32 cancerexpression.
free individuals. Although we did not measure CYP1A1 protein levels or CYP1A1 enzyme activity, mRNA levels and enzyme activities are known to be closely related (14,15). The case specimens were derived from 22 mastectomies (peripheral Polycyclic aromatic hydrocarbons (PAHs), a class of chemicals non-tumor tissue) and five contralateral to carcinomatous that includes potent carcinogens, could have a role in breast breast. The control specimens were obtained from 32 reduction cancer because they accumulate in breast adipose tissue (1) mammoplasties. Tissue specimens were dissected and isolated and because normal human mammary cells in culture activate from adipose and connective tissue, so that only epithelial PAHs efficiently (2) . PAH-DNA adduct levels have been found material was stored frozen as organoids (16). The pathological to be significantly higher in normal breast tissue of breast diagnosis of the excised tumors was intraductal carcinomas cancer patients than in that of non-cancer controls (3). The for two cases and infiltrating ductal carcinoma for the other mutational spectrum in the p53 gene in breast tumors resembles 20 cases. In two of the 22 cases, metastasis to axillary that of lung cancers where there is a well-established role for lymph nodes was observed, indicating more advanced disease. environmental agents, such as tobacco smoke (4). The major Samples were collected without respect to age and race. Only metabolic pathway for ingested or inhaled PAHs to waterthe age and disease status of the specimen donors are known. soluble derivatives is oxidative activation by CYP1A1 followed
No information is available on donors' race, lifestyle, smoking by detoxification by phase II enzymes. There is evidence habits or other potential confounding factors. Individuals supporting a role of CYP1A1 in breast cancer from recent undergoing reduction mammoplasty ranged in age from 15 to animal experiments: using a rat model to identify loci that 68 years, and mastectomy patients ranged in age from 30 to control breast cancer susceptibility, one of the four loci mapped 87 years. to CYP1A1 or a nearby locus (5) .
To determine CYP1A1 transcript levels, we developed a reverse transcription-polymerase chain reaction (RT-PCR)
Abbreviations: CYP1A1, cytochrome P4501A1; PAHs, polycyclic aromatic hydrocarbons.
assay that determines CYP1A1 expression relative to the Fig. 1 . Polyacrylamide gel of CYP1A1 and β-actin PCR products for three specimens. The cDNA from each specimen was diluted serially five-fold and several of these dilutions were amplified for each specimen. Lane 1, molecular weight standard; lanes 2-6, specimen 86P peripheral to tumor; lanes 7-10, specimen 71C contralateral; lanes 11-13, 184 cells that were included in each reaction as control to test for interexperimental variation; lane 14, negative control. constantly expressed β-actin gene, thus controlling for varying sample sizes and RNA yield. Previously published primers designed to span an intron (thus excluding amplification of any contaminating genomic DNA) were used and generated products of 320 bp for CYP1A1 and 273 bp for β-actin (17, 18) . PCR conditions and cycle numbers were optimized separately for each target sequence to ensure that the reaction was in the linear phase of product accumulation. A five-fold serial dilution of cDNA was amplified in separate reactions for CYP1A1 and β-actin. After amplification, the products were mixed together before electrophoresis on a 10% native polyacrylamide gel. The gel was stained with SYBR Gold nucleic acid stain and scanned on a Molecular Dynamics STORM 860 optical scanner. The fluorescent signal for each band was quantified using ImageQuant software (Figure 1 ). We found that this assay for CYP1A1 expression is sensitive, reproducible and has a broad dynamic range. CYP1A1 expression was measured in 59 nontumor breast tissues from individuals with breast cancer (n ϭ 27) and from cancer-free individuals (n ϭ 32). Only one of the 59 samples did not have amplifiable RNA. CYP1A1 quantification was repeated in a blinded assay for 20% of samples. The correlation between the original measurements and the respective repeats was 0.9878, indicating that the assay exposure, whereas CYP1A1 transcript levels increase in proportion to the dose (data not shown). In the present study, β-actin aryl hydrocarbon receptor and the estrogen receptor pathways transcript levels in the 58 specimens could be evaluated from has been observed in several systems (13). one of the first two dilutions of the cDNA. In contrast, the CYP1A1 expression, represented by the CYP1A1:β-actin whole range of dilutions was needed to determine the CYP1A1 transcript ratio, differed between groups: The arithmetic mean transcript levels in all specimens, indicating the large variations of the CYP1A1:β-actin ratio was 9.55 (SD ϭ 14.66) in specimens between individuals in CYP1A1 expression. The CYP1A1:β-from breast cancer patients and 6.31 (SD ϭ 6.91) in specimens actin transcript ratio varied between the lowest value of 0.17 from cancer-free individuals. This difference was not statisticto the highest value of 70, a Ͼ400-fold range. As seen in ally significant (in a two-tailed t-test, t was -1.11 and P 0.27) Figure 2 , individuals in the control group were younger than in the small sample studied. Comparing the distribution of those in the case group, but CYP1A1 expression did not change CYP1A1:β-actin values, a fairly log-normal distribution of with the age of the donors. The correlation coefficient for the values is seen for cases and controls ( Figure 3 ). The geometric CYP1A1:β-actin transcript ratio and age was -0.0357 for mean of the CYP1A1:β-actin ratio was 3.70 (SD ϭ 4.90) in cancer patients and 0.0434 for controls, constituting persuasive cases and 3.15 (SD ϭ 4.05) in controls. evidence that CYP1A1 level and age are not correlated. The
The large variation between individuals in CYP1A1 expreslack of a correlation with age indicates that the reduction in sion might be explained by unmeasured environmental or estrogen levels experienced with menopause does not influence lifestyle factors, such as smoking, which is known to induce CYP1A1 expression. CYP1A1 expression is increased in lung the CYP1A1 level, even though an interaction between the tissue of patients with tobacco-induced lung cancer (19).
human recombinant CYP1A1*1 and CYP1A1*2, a more recent study did not find different benzo[a]pyrene activation (23). Others have reported variation in CYP1A1 expression in lung tissue (15,20,21), including a recent report that found that Another study reported no difference in the kinetics of the CYP1A1 polymorphic variants (24). Therefore, any change in CYP1A1 expression in females was more than twice that in males (22).
CYP1A1 level in CYP1A1*3 seems to be the result of strict linkage to CYP1A1*2 polymorphism (7), which presumably The CYP1A1*2 and CYP1A1*3 alleles have been associated with a phenotype of high gene induction in response to PAHs alters the inducibility of the enzyme. Our data suggest that CYP1A1*2 polymorphism has a minor, if any, role in modifying (11) . To investigate to what extent the CYP1A1 genotype modifies CYP1A1 expression, the CYP1A1 genotype of all CYP1A1 expression (Figure 4 ). If individuals with the CYP1A1 variant genotype were exposed to much lower levels of PAHs specimens was determined using PCR/restriction fragment length polymorphism analysis according to published procedthan individuals with the wild-type genotype, the impact of genotype on expression might be masked. In an earlier study, ures (7) . A total of eight CYP1A1*2 and CYP1A1*3 alleles in 58 samples were detected: three CYP1A1*2 heterozygotes, human mammary epithelial cells derived from 18 individuals were treated with benzo[a]pyrene and DNA adducts quantified three CYP1A1*2/ CYP1A1*1 heterozygotes and two CYP1A1*2 homozygotes. The case group had only one CYP1A1*2/ (2). Among the strains examined were six derived from donors tested here for CYP1A1 expression and CYP1A1 genotype, CYP1A1*1 heterozygote while the control group had seven variants. When all CYP1A1 values are ranked (Figure 4) , the including the two homozygous CYP1A1*2 and one of the heterozygous CYP1A1*2 variants identified here. Contrary to CYP1A1 variants are distributed between the lowest and highest expression values. All heterozygous variants and the one expectations, the two homozygous CYP1A1*2 alleles had the lowest amount of adducts, indicating that the CYP1A1*2 homozygous CYP1A1*2 variant have CYP1A1 values below the mean CYP1A1 values. Only one homozygous CYP1A1*2 genotype did not increase DNA adduct formation. Besides activating xenobiotics, CYP1A1 also metabolizes 17 β-estravariant was among the five specimens with the highest CYP1A1 expression values, indicating that the polymorphism has at diol to the less active 2-hydroxy estradiol (25). A recent study suggests that CYP1A1*2 may be a marker of altered estradiol most a minor role in determining CYP1A1 expression.
The CYP1A1*2 variant is located in the non-coding region metabolism and of increased susceptibility to estrogen-related breast cancer in African-Americans (26). of the gene, suggesting that the CYP1A1*2 polymorphism alters the inducibility of CYP1A1. The CYP1A1*3 variant is
In conclusion, this study shows that breast tissue expresses a considerable range of CYP1A1 levels independent of age located in exon 7, which codes for the heme-binding region. A change in amino acids in this region could possibly result and genotype, reinforcing the importance of evaluating both genotype and phenotype. Although the results are not statisticin a change in enzyme activity. An earlier study reported a 50% higher enzyme activity (11). However, using purified ally significant in the small unselected specimen groups avail- 
